AstraZeneca Likes Sound Of Silence's Science
UK Biotech Gets $80m Upfront
Executive Summary
The UK major is getting access to Silence's small interfering RNA (siRNA) platform while the London-based biotech is getting further validation of its technology and a considerable pile of cash.
You may also be interested in...
Silence Therapeutics Could Rival Amgen And Novartis With siRNA Therapy
The UK biotech could have a major gene silencing drug on its hands but will need a big pharma partner to help it realize the candidate’s potential.
In Vivo’s Deals Of The Year 2020: Cast Your Vote!
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
UK Biotechs Maintain Fundraising During Pandemic
Buoyed by belief in its strengths, the UK biotech sector has defied the pandemic over the last three months – but smaller firms are still strapped for cash.